| Document |
Document Title |
|
WO/2023/171789A1 |
The present addresses the problem of providing a novel composition for treating myocarditis and/or a novel composition for preventing myocarditis. Provided is a composition for preventing or treating myocarditis, the composition compri...
|
|
WO/2023/169899A1 |
The present invention relates generally to the field of molecular biology and therapeutics. More specifically, the present invention relates to a novel targeting bio-conjugate for selective delivery of therapeutic nucleic acids, includin...
|
|
WO/2023/172628A1 |
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for modulating an immune response to an anti...
|
|
WO/2023/170187A1 |
The invention refers to an inhibitor of the IκB kinase-α (IKK-α)/ NF-κB-inducing kinase (NIK) complex for use in preventing or treating infection, in particular viral or bacterial infection in a cell and/or subject, in particular for...
|
|
WO/2023/167560A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, the composition containing VEGF-Grab as an active ingredient, and being intended for administration in combination with a PD-1 or PD-L1 anta...
|
|
WO/2023/166492A2 |
The present invention generally relates to the use of a dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan-2,3-dioxygenase (TDO), either alone or in combination with other agents, and pharmaceutical compositions compri...
|
|
WO/2023/165870A1 |
A method of improving and/or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprisi...
|
|
WO/2023/166077A1 |
The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.
|
|
WO/2023/168201A1 |
Embodiments of the invention relate generally to the treatment of tumors and, more particularly, to the use of trichostatin A (TSA) in tumor treatment.
|
|
WO/2023/165603A1 |
Use of a DNA-PK inhibitor, alone or in combination with one or more additional therapy, in the treatment of cancer.
|
|
WO/2023/166161A1 |
Present invention relates to a novel composition and treatment regimen in treatment of bacterial infections.
|
|
WO/2023/166348A1 |
Described herein are uses of crystalline forms of 2-(4-methoxy-3 -(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxyl
ic acid in the treatment of diseases or conditions that would benefit by administration with an LPA1 recep...
|
|
WO/2023/166078A1 |
The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a CHEK1 inhibitor.
|
|
WO/2023/167033A1 |
Provided is a prorenin receptor peptide having enhanced ability to induce an antibody against a prorenin receptor. The prorenin receptor peptide of the present disclosure includes the following polypeptide (P1), (P2) or (P3): (P1) a po...
|
|
WO/2023/165149A1 |
An "immune exosome" nanoparticle loaded with traditional Chinese medicine self-assembled micelles, and a preparation method therefor and an application thereof; the nanoparticle is mainly formed by coating an exosome membrane modified by...
|
|
WO/2023/166080A1 |
The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a WEE1 inhibitor.
|
|
WO/2023/168020A1 |
The invention discloses a treatment composition to treat nasal or oral dryness and allergy symptoms, and a method for using the same. Certain compositions include xylitol, at least two wetting agents, an aqueous carrier, and other active...
|
|
WO/2023/166153A1 |
There is provided a compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof.
|
|
WO/2023/167655A1 |
The present invention relates to a culture medium and a method using the said medium for obtaining motor neuron cells from human pluripotent stem cell- derived neuromesodermal stem cells (NMSCs). Furthermore, the present invention relate...
|
|
WO/2023/167364A1 |
The present invention relates to: a photosensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for a photosensitive hydrogel for cancer treatment. Th...
|
|
WO/2023/168420A1 |
Provided herein are methods of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of a STAT inhibitor and an effective amount of an immune checkpoint inhibitor (e.g., PD-1 inhibito...
|
|
WO/2023/166487A1 |
Described herein are methods of treating lupus nephritis with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.
|
|
WO/2023/161314A1 |
The present invention concerns the use of [(2S)-l-(4-{[(3-chloro-4- methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carba
moyl}pyrimidin-2-yl) pyrrolidin-2-yl]methyl 6-(nitrooxy)hexanoate for the treatment of anterior ischemic opt...
|
|
WO/2023/163227A1 |
The present invention provides a linker, a linker/payload, an antibody-drug conjugate, and an antitumor drug that are novel. Specifically, the present invention provides an antibody-drug conjugate that is represented by general formula (...
|
|
WO/2023/161264A1 |
The present disclosure relates to the use of a combination of a known neuronal exocytosis inhibitor, and a known TRPV1 modulator in the treatment and/or prevention of diseases or conditions that courses through an excessive neural stimul...
|
|
WO/2023/162872A1 |
This anticancer drug contains an ATP8B2 inhibitor.
|
|
WO/2023/164386A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/163187A1 |
The present invention provides: an anti-gpNMB antibody that binds to gpNMB and affects the same and that has an effect of such as removal of dysfunctional microglia; and a use application of the anti-gpNMB antibody. The anti-gpNMB antibo...
|
|
WO/2023/160029A1 |
The present invention provides use of atractylenolide I in the preparation of a medicine for preventing and/or treating cervical cancer, and belongs to the technical field of chemical medicines. Specifically provided is use of a compound...
|
|
WO/2023/161887A1 |
The present disclosure relates to methods for treating and/or preventing Hidradenitis Suppurativa in a subject having such disease or condition comprising administering a therapeutically effective dose of LOU064. Also disclosed are medic...
|
|
WO/2023/164385A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/162952A1 |
A method for detecting a marker for diagnosing the disease progression of peritoneal fibrosis, said method involving the detection of the amount of osteopontin present from a peritoneal dialysis drainage fluid used in peritoneal dialysis...
|
|
WO/2023/163879A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/163234A1 |
The present invention provides: a method for improving the stability of an antibody-drug conjugate in vivo; and a conjugate precursor for producing a stabilized antibody-drug conjugate. More specifically, the present invention provides: ...
|
|
WO/2023/163087A1 |
The purpose of the present invention is to provide a medicine exhibiting a satisfactory anti-cancer effect by combining an antibody capable of binding to a mutant CALR protein with another anti-cancer agent. Provided is a medicine for ...
|
|
WO/2023/161350A1 |
The present invention relates to mRNAs useful in cancer therapies as well as mRNAs for use in a method for the prevention or treatment of cancer in a subject.
|
|
WO/2023/163475A1 |
The present invention relates to a novel immuno-oncology agent which has an immuno-oncology effect alone and of which the effect is further improved when used in combined treatment with an immune checkpoint inhibitor. Ruboxistaurin accor...
|
|
WO/2023/046060A9 |
A method for treating cancer and tumor patients having KRAS mutations, and pharmaceutical use.
|
|
WO/2023/164548A1 |
Methods and compositions for treating a disease or disorder (e.g., organ fibrosis, nephropathy) by administering an inhibitor of IL-6 activity are provided.
|
|
WO/2023/164387A1 |
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
|
|
WO/2023/161326A1 |
The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopat...
|
|
WO/2023/163988A1 |
The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.
|
|
WO/2023/164151A1 |
Methods of treating lung cancer in a subject in need thereof are provided, including administering to the subject an effective amount of an imidazolate gold compound according to Formula I, or a pharmaceutically acceptable salt, racemate...
|
|
WO/2023/161427A1 |
This application describes the medical use of a combination treatment for infections through the inhibition of helicases, especially viral helicases, in combination with the inhibition of viral nucleic acid polymerases. In particular, th...
|
|
WO/2023/158290A1 |
The present application relates to: a compound of chemical formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof; and use thereof for preventing, alleviating and/or treating inflammasome-mediated diseases and/or gram...
|
|
WO/2023/155862A1 |
The present invention relates to the technical field of biopharmaceutics and vaccines, and in particular, to an aluminum-based self-assembled delivery system for mRNA, a method for preparing same, and use thereof. The aluminum-based self...
|
|
WO/2023/159040A1 |
The present application relates to crystal forms of (+)-tetrabenazine. The present application also relates to a pharmaceutical composition comprising the crystal form of (+)- tetrabenazine, as well as methods of using the crystal forms ...
|
|
WO/2023/159066A1 |
The present invention provides methods of administering niraparib for the treatment of primary and metastatic brain cancer.
|
|
WO/2023/155757A1 |
Provided is use of sarsasapogenin compounds in the preparation of a medicine for treating related diseases caused by mitochondrial dysfunction, wherein the structural formula of the compounds is shown in general formula (I). The activity...
|
|
WO/2023/156808A2 |
The present invention relates to pharmaceutical compositions and methods useful for treating pulmonary disorders, including asthma, chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOD), or any other respirato...
|
